培美曲塞联合奈达铂化疗在晚期肺腺癌患者治疗中的应用效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application effects of Pemetrexed combined with Nedaplatin chemotherapy in the treatment of patients with advanced lung adenocarcinoma.Methods A total of 60 patients with advanced lung adenocarcinoma treated in department of medical oncology of our hospital from February 2014 to February 2015 were selected as the subjects,and randomly divided into treatment group and control group,with 30 cases in each group.The control group was treated with Gemcitabine combined with Nedaplatin chemotherapy,and the treatment group was given Pemetrexed combined with Nedaplatin chemotherapy.The effective rate of treatment,serum tumor marker levels before and after treatment and occurrence of adverse reactions were compared between the two groups.Patients were given 4 to 24 months of outpatient or telephone follow-up,and the overall survival time was recorded of the two groups.Results The total effective rate of treatment in treatment group (63.33%)was higher than that in control group (36.67%)(P＜0.05).The levels of serum carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),carbohydrate antigen 50(CA50)and carbohydrate antigen(CA199)in treatment group were lower than those in control group after treatment(P＜0.05).The incidence rates of alopecia,rash,leukopenia,neutropenia,thrombocytopenia,liver and kidney function damage and nausea and vomiting in treatment group were lower than those in control group (P＜0.05).The overall survival time in treatment group was(18.56±4.67)months,which was longer than that in control group ([14.29±4.72]months)(P＜0.05).Conclusion Pemetrexed combined with Nedaplatin chemotherapy has significant efficacy in the treatment of advanced lung adenocarcinoma,and it can effectively improve serum tumor markers levels and prolong survival time.

Key words： Lung adenocarcinoma chemotherapy Pemetrexed Gemcitabine Nedaplatin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Ding-hong
	LIN Chang-yu
	HUANG Xiao-long

Cite this article:

YANG Ding-hong,LIN Chang-yu,HUANG Xiao-long. Application effects of Pemetrexed combined with Nedaplatin chemotherapy in the treatment of patients with advanced lung adenocarcinoma[J]. 中国当代医药, 2019, 26(17): 61-64.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I17/61

[1]	昂盛骏，熊丽林，唐萌，等.PM_（2.5）对人肺腺癌 A549 细胞iNOS合成的影响及其作用机制[J].环境与职业医学，2016，33（5）：433-437.
[2]	马汉宸，隋东昕，徐少华，等.晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效[J].山东医药，2016，56（33）：99-101.
[3]	周毅，周健，张莹，等.培美曲塞联合奈达铂治疗晚期肺腺癌临床疗效及其安全性观察[J].第三军医大学学报，2018，40（13）：1236-1241.
[4]	国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读[J].肿瘤防治研究，2016，43（4）：313-318.
[5]	张余飞，康静波，温居一，等.RECIST 1.1标准和mRECIST标准在原发性肝癌SBRT治疗后疗效评价中的对比研究[J].中国肿瘤临床，2016，43（20）：902-906.
[6]	彭培建，林忠，张红雨，等.厄罗替尼治疗晚期非小细胞肺癌患者的疗效及安全性研究[J].中国全科医学，2010，13（13）：1420-1423.
[7]	杨佳，顾国民，王秀丽，等.自体肿瘤抗原致敏DC-CIK联合化疗治疗晚期肺腺癌的疗效[J].中国肿瘤生物治疗杂志，2016，23（1）：83-88.
[8]	张冬丽，李艳云，田君，等.紫杉醇注射液联合奈达铂注射剂治疗晚期复发转移性宫颈癌的临床研究[J].中国临床药理学杂志，2017，33（13）：1188-1190.
[9]	张雅军，徐锋，韩纪昌，等.培美曲塞联合紫杉醇和顺铂治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志，2016，32（15）：1396-1399.
[10]	许斌，张倩玉.吉西他滨在恶性肿瘤治疗中的免疫调节作用[J].重庆医学，2017，46（23）：3293-3296.
[11]	曹运锋，石凡英，郭春辉，等.培美曲塞和吉西他滨分别联合奈达铂治疗晚期肺腺癌的疗效及安全性比较[J].国际呼吸杂志，2016，36（11）：810-813.
[12]	康睿，王莉，李林娟，等.厄洛替尼、奈达铂联合培美曲塞治疗晚期非小细胞肺癌临床疗效及其对患者免疫功能的研究[J].临床和实验医学杂志，2016，15（17）：1690-1692.
[13]	卢素琼，顾国民，王秀丽，等.培美曲塞联合奈达铂一线治疗晚期肺腺癌的临床观察[J].现代肿瘤医学，2016，24（12）：1905-1907.
[14]	李友涛，万仁平，黄淼龙，等.奈达铂分别联合紫杉醇和培美曲塞一线治疗肺腺癌的临床效果比较[J].实用癌症杂志.2018，33（6）：931-934.
[15]	卢奕宇，邓瑾，杨文，等.培美曲塞联合奈达铂或顺铂同步调强放疗治疗晚期肺腺癌临床疗效的对比研究[J].实用心脑肺血管病杂志，2016，24（11）：64-67.